• Cancel
    Date：2021-04
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=819

    On April 12, SUNING LSY announced the successful closing of a significant Series A financing with investment from CPE and ADV Partners. CEC Capital Group served as the exclusive financial advisor in this transaction for SUNING LSY.

  • Cancel
    Date：2021-03
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=560

    PALO ALTO, CA, March 30, 2021 -- Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting immunosuppressive myeloid checkpoints today announced the closing of a $73 million Series B1/2 financing. The round was led by Oceanpine Capital with participation from additional new investors including Octagon Capital and Sphera Funds Management, and existing investors, including Northern Light Venture Capital and Vivo Capital. In addition, the company received a strategic capital investment from The Leukemia & Lymphoma Society’s Therapy Acceleration Program® (LLS TAP), directed toward advancing the company’s work to treat blood cancers. CEC Capital Group was the exclusive financial advisor on this transaction.

  • Cancel
    Date：2021-03
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=821

    HISTO, the first independent third-party pathology diagnostic center in China, recently announced the closing of its B round financing, raising over RMB 100 million. The round was led by Haier Medical with participation from Flyfot Ventures and other well

  • Cancel
    Date：2021-03
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=822

    Shanghai Cell Therapy Group, a leading player in the cell therapy industry in China, has announced the successful closing of its Series D1 financing, raising nearly RMB 500 million. The round was jointly invested by Jiuzhou Venture, Sun Rock Capital, and

  • Cancel
    Date：2021-03
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=823

    Thousand Oaks, a rapidly growing Contract Development and Manufacturing Organization (CDMO) and cell culture biotechnology company, announced today that it has raised over RMB 400 million in its Series C Financing in March 2021. This round of financing wa

  • Cancel
    Date：2021-03
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=824

    Arctic Vision, a clinical-stage biotech company focused on innovative ophthalmology therapies, announced today that it has successfully raised over $100 million in B round financing. The financing was led by Loyal Valley Capital, with participation from T

  • Cancel
    Date：2021-03
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=825

    Gensciences Group announced the closing of over RMB 800 million in Series A and B financings. The B round financing was led by HT Capital, with participation from Efung Capital and Huarong Rongde. Existing A round shareholders IDG Capital, New Alliance Ca

  • Cancel
    Date：2021-02
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=831

    On February 24, 2021, YS Biopharma announced the closing of over $130 million in its Series B financing. This round of investment was jointly led by Oceanpine and OrbiMed. Following the Series B financing, the company's institutional investors include Oce

  • Cancel
    Date：2021-02
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=826

    WuXi Diagnostic rasied $150 million in its Seris B financing, led by Shiyu Investment, Thermo Fisher Scientific, ABC International, Sunland Fund, CCB Sci-Tech Innovation Fund, with continued support from existing shareholder Yunfeng Capital. The funds fro